Since the B-Raf and MEK inhibitors are so far the most successful in clinical use of anticancer therapy while investigations of B-raf inhibitors are mostly focused on B-Raf V600E mutation, it is feasible to repurpose the MEK inhibitors for antiviral infections. This evidence concerns the gene BRAF and infection.